Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.antiviral.2020.104787 http://scihub22266oqcxt.onion/10.1016/j.antiviral.2020.104787 32251768!7129059!32251768     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32251768&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Antiviral+Res 2020 ; 178 (?): 104787 Nephropedia Template TP {{tp|p=32251768|t=2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |pdf=|usr=}}{{32251768}} gab.com Text The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro JO: Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=32251768 #FOAvip Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans. Twit Text FOAVip The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro ????Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=32251768 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32251768 #FOAvip English Wikipedia <ref>{{Cite pmid|32251768}}</ref> The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro #MMPMID32251768 Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM Antiviral Res 2020[Jun]; 178 (?): 104787 PMID32251768show ga Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans. |*Drug Approval[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |Australia[MESH] |Betacoronavirus/*drug effects/physiology[MESH] |COVID-19[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Infections/drug therapy/*virology[MESH] |Humans[MESH] |Ivermectin/*pharmacology/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy/*virology[MESH] |SARS-CoV-2[MESH] |Vero Cells[MESH]The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-(epmc).pdf DeepDyve Pubget Overpricing